Literature DB >> 12365579

Rapid molecular diagnosis of tuberculous meningitis using the Gen-probe Amplified Mycobacterium Tuberculosis direct test in a large Canadian public health laboratory.

P Chedore1, F B Jamieson.   

Abstract

OBJECTIVE: A 5-year retrospective study of the performance of the Gen-Probe Amplified Mycobacterium Tuberculosis Direct Test (MTD) for detecting Mycobacterium tuberculosis complex in cerebrospinal fluid (CSF). Patient data from culture-confirmed cases of tuberculous meningitis (TBM) were also analysed.
RESULTS: In total, 311 CSF specimens were tested by the MTD, of which 17 were positive. When compared with culture (gold standard), the sensitivity and specificity of the MTD test were 93.8% and 99.3%, respectively. The positive and negative predictive values for TBM were 88.2%, and 99.7%. Clinical and epidemiological information was requested for all culture-positive TBM patients. These data were used to assess the mortality rate (55.6%) and to determine common factors that could be applied as selection criteria for the appropriate testing of CSF by MTD.
CONCLUSION: The study found the MTD test to be a rapid, sensitive and specific test for TBM. A history of immigration from an area endemic for tuberculosis (TB), a history of TB, symptoms of neurological deficits and the results of CSF analyses could be used to appropriately select CSF for MTD testing in order to provide a critical early diagnosis of TBM.

Entities:  

Mesh:

Year:  2002        PMID: 12365579

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  9 in total

Review 1.  Relevance of commercial amplification methods for direct detection of Mycobacterium tuberculosis complex in clinical samples.

Authors:  Claudio Piersimoni; Claudio Scarparo
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

2.  A 20-year-old woman with headache and transient numbness.

Authors:  Kenneth L Tyler; Erik C B Johnson; David S Cantu; Barbara L Haller
Journal:  Neurohospitalist       Date:  2013-04

3.  A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Nucleic Acid Amplification Tests for Tuberculous Meningitis.

Authors:  Ali Pormohammad; Mohammad Javad Nasiri; Timothy D McHugh; Seyed Mohammad Riahi; Nathan C Bahr
Journal:  J Clin Microbiol       Date:  2019-05-24       Impact factor: 5.948

Review 4.  Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities.

Authors:  Linda M Parsons; Akos Somoskövi; Cristina Gutierrez; Evan Lee; C N Paramasivan; Alash'le Abimiku; Steven Spector; Giorgio Roscigno; John Nkengasong
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

5.  Improved sensitivity of nucleic acid amplification for rapid diagnosis of tuberculous meningitis.

Authors:  Isik Somuncu Johansen; Bettina Lundgren; Fehmi Tabak; Björn Petrini; Salih Hosoglu; Nese Saltoglu; Vibeke Østergaard Thomsen
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

6.  Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuberculous meningitis before and after inception of antituberculosis chemotherapy.

Authors:  Guy E Thwaites; Maxine Caws; Tran Thi Hong Chau; Nguyen Thi Dung; James I Campbell; Nguyen Hoan Phu; Tran Tinh Hien; Nicholas J White; Jeremy J Farrar
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

Review 7.  Central nervous system tuberculosis: pathogenesis and clinical aspects.

Authors:  R Bryan Rock; Michael Olin; Cristina A Baker; Thomas W Molitor; Phillip K Peterson
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

8.  The PCR-Based Diagnosis of Central Nervous System Tuberculosis: Up to Date.

Authors:  Teruyuki Takahashi; Masato Tamura; Toshiaki Takasu
Journal:  Tuberc Res Treat       Date:  2012-05-13

Review 9.  Chronic meningitis.

Authors:  Bruce A Cohen
Journal:  Curr Neurol Neurosci Rep       Date:  2005-11       Impact factor: 6.030

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.